Evidence map›Paper›PMID 40238217›Full record

ArticleJNCI cancer spectrum2025

Guideline-concordant treatment among adolescents and young adults with acute lymphoblastic leukemia.

Julie A Wolfson, Allison C Grimes, Michelle M Nuño, Subhash Ramakrishnan, David S Dickens, Michael E Roth, Wendy Woods, Kandice S Adams, Tawa Alabi, Melissa Beauchemin and 17 more

Abstract read
In one paragraph

Article in JNCI cancer spectrum, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

27 authors.

Julie A WolfsonDivision of Pediatric Hematology-Oncology, University of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0002-3711-2239
Allison C GrimesDivision of Pediatric Hematology-Oncology, University of Texas Health Science Center San Antonio, San Antonio, TX, United States.ORCID 0000-0001-5729-2778
Michelle M NuñoChildren's Oncology Group, Monrovia, CA, United States.ORCID 0000-0003-2031-929X
Subhash RamakrishnanChildren's Oncology Group, Monrovia, CA, United States.ORCID 0009-0006-5801-8985
David S DickensDivision of Pediatric Hematology-Oncology, University of Iowa, Iowa City, IA, United States.ORCID 0000-0001-8821-6022
Michael E RothDivision of Pediatric Oncology, MD Anderson Cancer Center, Houston, TX, United States.ORCID 0000-0002-6411-8353
Wendy WoodsDivision of Pediatric Hematology-Oncology, Blank Children's Hospital, Des Moines, IA, United States.ORCID 0000-0002-6280-5360
Kandice S AdamsInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, United States.ORCID 0000-0002-5867-8485
Tawa AlabiInstitute for Cancer Outcomes and Survivorship, University of Alabama at Birmingham, Birmingham, AL, United States.
Melissa BeaucheminSchool of Nursing, Columbia University Irving Medical Center, New York, NY, United States.ORCID 0000-0003-4058-1586
Jennifer M LevineCenter for Cancer and Blood Disorders, Children's National Medical Center, Washington, DC, United States.
Michele SciallaCenter for Healthcare Delivery Science, Nemours Children's Hospital, Delaware, Wilmington, DE, United States.ORCID 0000-0001-7933-0675
Koh B BoayueDivision of Pediatric Hematology-Oncology, University of New Mexico Cancer Center, Albuquerque, NM, United States.
Charlotte L KerberDepartment of Public Health Sciences, University of California, Davis, Davis, CA, United States.ORCID 0000-0003-3937-2736
Olivia PonceChildren's Oncology Group, Monrovia, CA, United States.
Sarah VargasChildren's Oncology Group, Monrovia, CA, United States.
George J ChangDepartment of Colon and Rectal Surgery and Department of Health Services Research, The University of Texas, MD Anderson Cancer Center, Houston, TX, United States.ORCID 0000-0002-9758-5361
Wendy StockDivision of Hematology-Oncology, University of Chicago Medicine, Chicago, IL, United States.ORCID 0000-0002-8349-9200
Dawn HershmanDivision of Hematology-Oncology, Columbia University, New York, NY, United States.ORCID 0000-0001-8807-153X
Emily CurranDivision of Hematology-Oncology, University of Cincinnati, Cincinnati, OH, United States.
Anjali AdvaniDivision of Hematology-Oncology, Cleveland Clinic, Taussig Cancer Institute, Cleveland, OH, USA.
Kristen O'DwyerDivision of Hematology-Oncology, University of Rochester, Wilmot Cancer Institute, Rochester, NY, United States.ORCID 0000-0001-8517-8198
Selina LugerDivision of Hematology-Oncology, University of Pennsylvania, Philadelphia, PA, USA.ORCID 0000-0003-3364-4366
Jane Jijun LiuHeartland National Cancer Institute Community Oncology Research Program, Illinois CancerCare, Peoria, IL, United States.
David R FreyerDivision of Pediatric Hematology-Oncology, Children's Hospital Los Angeles, Los Angeles, CA, United States.ORCID 0000-0001-5280-990X
Lillian SungDivision of Haematology/Oncology, The Hospital for Sick Children, Toronto, ON, Canada.ORCID 0000-0003-0951-3091
Susan K ParsonsDivision of Hematology/Oncology and Institute for Clinical Research and Health Policy Studies, Tufts Medical Center, Boston, MA, United States.ORCID 0000-0003-0282-6490

Funding

NCTN BIQSFP ANBL1531 (NRT)U10CA180886 · NCI · PUBLIC HEALTH INSTITUTE · PI Douglas S. Hawkins · 2014 to 2026
$390.6M
ECOG-ACRIN NCORP Research Base - TMISTUG1CA189828 · NCI · ECOG-ACRIN MEDICAL RESEARCH FOUNDATION · PI Peter J ODwyer, MITCHELL D. SCHNALL · 2014 to 2026
$199.7M
SWOG Network Group Operations Center of the NCTNU10CA180888 · NCI · UNIVERSITY OF CALIFORNIA AT DAVIS · PI PRIMO N. LARA · 2014 to 2026
$152.1M
COG SDMC - Statistics CoreU10CA180899 · NCI · UNIVERSITY OF SOUTHERN CALIFORNIA · PI TODD A ALONZO · 2014 to 2026
$132.8M
Collaborations and NCORP Collective ManagementUG1CA189823 · NCI · MAYO CLINIC ROCHESTER · PI Evanthia Galanis, Olwen Hahn · 2014 to 2026
$120.6M
SWOG NCORP Research BaseUG1CA189974 · NCI · THE HOPE FOUNDATION · PI CHARLES D. BLANKE, DAWN HERSHMAN · 2014 to 2026
$80.6M
Towards a preventive cancer vaccine for children with constitutional mismatch repair deficiencyUG1CA189955 · NCI · PUBLIC HEALTH INSTITUTE · PI BRAD H POLLOCK, Michael E. Roth · 2014 to 2026
$62.5M
Alliance for Clinical Trials in Oncology UG1CA189823Children's Oncology GroupChildren's Oncology Group U10CA180886Children's Oncology Group U10CA180899ECOG-ACRIN UG1CA189828NCI Community Oncology Research ProgramNCI NIH HHS U10 CA180886NCI NIH HHS U10 CA180888NCI NIH HHS U10 CA180899NCI NIH HHS UG1 CA189823NCI NIH HHS UG1 CA189828NCI NIH HHS UG1 CA189955NCI NIH HHS UG1 CA189974Research Base UG1CA189955SWOG UG1CA189974
6 · The paper itself

Abstract

backgroundIndividuals diagnosed with acute lymphoblastic leukemia (ALL) between adolescents and young adults aged 15-39 years face poor survival and unique challenges. We evaluated facility-level factors and guideline-concordant care among adolescents and young adults with ALL at National Cancer Institute Community Oncology Research Program (NCORP) practices.

methodsWe assembled a retrospective cohort of adolescents and young adults aged 15-39 years with ALL treated at participating NCORPs between 2012 and 2016. NCORPs abstracted patient data and completed facility-level questionnaires for each clinical facility (study-defined criteria). The central review committee adjudicated whether treatment was concordant with adolescent and young adult-specific National Comprehensive Cancer Network ALL guidelines (ie, pediatric-inspired therapy or clinical trial). Guideline-concordant care was described by age, facility model (adult/internal medicine, pediatric, mixed [pediatric services within a general hospital]), and average annual adolescents and young adult ALL volume. Generalized linear mixed effects models estimated the odds of guideline-concordant care.

resultsAdolescents and young adults receiving guideline-concordant care were younger (n = 196; median = 19.5 years) than those who did not (n = 31; median = 32.1 years). Guideline-concordant care was observed in many adolescents and young adults aged 22-39 years (68.8%), and nearly universal in those aged 15-21 years. In multivariable analyses, adolescents and young adults at adult/internal medicine clinical facilities had lower odds of guideline-concordant care (odds ratio = 0.02, 95% confidence interval = 0.0 to 0.18); there was no statistically significant association between annual adolescent and young ALL volume and receiving guideline-concordant care. Guideline-concordant care was observed more often in adult/internal medicine and/or mixed clinical facilities with communication between adult or pediatric counterparts, adolescents and young adult ALL clinical pathways, and/or adolescent and young adult-specific meetings.

conclusionGuideline-concordant care among adolescents and young adults with ALL (specifically pediatric-inspired therapy) at NCORPs is associated with facility model (adult/internal medicine) but not adolescent and young adult ALL volume. Strategies to improve guideline-concordant care could include facilitating communication and clinical pathways at adult/internal medicine clinical facilities treating adolescent and young adult ALL.

Indexed as

Guideline AdherencePrecursor Cell Lymphoblastic Leukemia-LymphomaAdolescentAdultAge FactorsFemaleHumansMalePractice Guidelines as TopicRetrospective StudiesUnited StatesYoung Adult

Identifiers

PMID40238217
PMCPMC12121638

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.